Cart
sales@molnova.com
(Z)-Butylidenephthalide
CAS No. 72917-31-8
(Z)-Butylidenephthalide( —— )
Catalog No. M37746 CAS No. 72917-31-8
(Z)-Butylidenephthalide ((Z)-3-Butylidenephthalide) has antitumor and hypoglycemic effects, and can effectively inhibit the tumor growth of glioma and inhibit R-glucosidase activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 187 | Get Quote |
|
| 5MG | 312 | Get Quote |
|
| 10MG | 471 | Get Quote |
|
| 25MG | 730 | Get Quote |
|
| 50MG | 984 | Get Quote |
|
| 100MG | 1305 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name(Z)-Butylidenephthalide
-
NoteResearch use only, not for human use.
-
Brief Description(Z)-Butylidenephthalide ((Z)-3-Butylidenephthalide) has antitumor and hypoglycemic effects, and can effectively inhibit the tumor growth of glioma and inhibit R-glucosidase activity.
-
Description(Z)-3-Butylidenephthalide is an antihyperglycemic agent by inhibiting the activity of intestinal and yeast R-glucosidases (IC50=2.35 mM; Ki=4.86 mM).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorGlucosidase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number72917-31-8
-
Formula Weight188.22
-
Molecular FormulaC12H12O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(\CCC)=C\1/C=2C(C(=O)O1)=CC=CC2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Fernando Brindis, et al. (Z)-3-butylidenephthalide from Ligusticum porteri , an α-glucosidase inhibitor. J Nat Prod. 2011 Mar 25;74(3):314-20. ?
molnova catalog
related products
-
AZD1208
AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases.
-
2-((9R10S11R15S)-121...
2-((9R10S11R15S)-1214-dioxo-910-dih is a chemical compound.
-
Ulixertinib
Ulixertinib (BVD-523, VRT752271) is an effective and reversible ERK1/ERK2 inhibitor. The IC50 of Ulixertinib is less than 0.3 nM for ERK2.
